| Literature DB >> 35328492 |
Daniela Grimm1,2,3,4, Herbert Schulz1,2,3, Marcus Krüger1,3, José Luis Cortés-Sánchez1, Marcel Egli5, Armin Kraus1,2,3, Jayashree Sahana4, Thomas J Corydon4,6, Ruth Hemmersbach7, Petra M Wise8, Manfred Infanger1,2,3, Markus Wehland1,2,3.
Abstract
Cancer is a disease exhibiting uncontrollable cell growth and spreading to other parts of the organism. It is a heavy, worldwide burden for mankind with high morbidity and mortality. Therefore, groundbreaking research and innovations are necessary. Research in space under microgravity (µg) conditions is a novel approach with the potential to fight cancer and develop future cancer therapies. Space travel is accompanied by adverse effects on our health, and there is a need to counteract these health problems. On the cellular level, studies have shown that real (r-) and simulated (s-) µg impact survival, apoptosis, proliferation, migration, and adhesion as well as the cytoskeleton, the extracellular matrix, focal adhesion, and growth factors in cancer cells. Moreover, the µg-environment induces in vitro 3D tumor models (multicellular spheroids and organoids) with a high potential for preclinical drug targeting, cancer drug development, and studying the processes of cancer progression and metastasis on a molecular level. This review focuses on the effects of r- and s-µg on different types of cells deriving from thyroid, breast, lung, skin, and prostate cancer, as well as tumors of the gastrointestinal tract. In addition, we summarize the current knowledge of the impact of µg on cancerous stem cells. The information demonstrates that µg has become an important new technology for increasing current knowledge of cancer biology.Entities:
Keywords: breast cancer; cancer stem cells; clinostat; colorectal cancer; liver cancer; microgravity; multicellular spheroids; omics studies; organoids; prostate cancer; random positioning machine; rotating wall vessel; spaceflight; thyroid cancer
Mesh:
Year: 2022 PMID: 35328492 PMCID: PMC8953941 DOI: 10.3390/ijms23063073
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Ground-based facilities: (A) 2D clinostat for adherent cells in slide flaks (Insert in A demonstrates residual accelerations depending on speed of rotation (here 60 rpm) and diameter) or (B) for suspended cells in pipettes. (C) Random Positioning Machines equipped with slide flasks (mL) for thyroid cancer cells. (D) NASA-developed Rotating Wall Vessel.
Figure 2Real microgravity platforms. (A): 37th DLR Parabolic flight campaign, Airbus A310 Zero-g aircraft from the company Novespace in Paderborn, Lippstadt Airport, on 18 July 2021, (B): the PFC flight rack with an incubator and (C): open door of the incubator and boxes containing the cell culture flasks with DU-145 PCC. (D): Payload of a TEXUS-type sounding rocket (SSC, ESRANGE, Kiruna, Sweden; (E): SpaceX CRS-8 rocket on the launch pad, Kennedy Space Center (KFC), FL, USA; (F): the International Space Station.
Overview of Results of Studies with Thyroid Cancer Cells.
| Cell Line | Biological Process | Genes/Proteins/Pathways | Microgravity | Reference |
|---|---|---|---|---|
| FTC-133 | Adhesion | VCAM1 | Space–CellBox-1 | [ |
|
| Space–CellBox-2 | [ | ||
| FTC-133 | Angiogenesis |
| Space–SimBox | [ |
| VEGF-A | Space–CellBox-1 | [ | ||
| Angiopoetin-2 | Space–CellBox-2 | [ | ||
| Space–CellBox-2 | [ | |||
| FTC-133 | Caveolae | CAV1 | Space–CellBox-1 | [ |
|
| Space–CellBox-2 | [ | ||
| FTC-133 | Extracellular Matrix |
| Space–SimBox, RPM | [ |
| TIMP1, MMP3 | Space–CellBox-1 | [ | ||
|
| Space–CellBox-2 | [ | ||
| FTC-133 | Cytokines |
| Space–SimBox, RPM | [ |
| IL6, IL8, IL7, IL18, MCP1, MIP-1 beta | Space–CellBox-1 | [ | ||
|
| Space–CellBox-2 | [ | ||
| ML1, RO82-W1 | IL6, MCP1 | RPM, Clinostat | [ | |
| IL6, IL8 | 1 | |||
| FTC-133 | Cell Signaling |
| Space–CellBox-2 | [ |
| FTC-133 | Protein Kinases |
| Space–SimBox, RPM | [ |
| FTC-133 | Growth Factors |
| Space–SimBox, RPM | [ |
|
| Space–CellBox-2 | [ | ||
| FTC-133 | Cytoskeleton | Space–TX52 | [ | |
| ML1 | PFC | [ | ||
| Cytokeratin, vimentin, tubulin | PFC | [ | ||
| FTC-133 | Exosomes, Exosomal miRNA | CD9, CD63, CD81 | Space-CellBox-1 | [ |
| Array scan of a total of 754 miRNA targets revealed more than 100 differentially expressed miRNAs: miR-199 family | Space-CellBox-1 | [ |
Genes and proteins, involved in BCC spheroid formation under microgravity conditions.
| Cell Line | Biolog. Process | Genes/Proteins/Pathways Major Result | Microgravity | Ref. |
|---|---|---|---|---|
| MCF-7 | Cytoskeleton | Upregulation of | r-μ | [ |
| MDA-MB231 | Cell adhesion | Upregulation of | r-μ | [ |
| MCF-7 | ECM, Cell cycle, Proliferation | Loosely organized perinuclear cytokeratin network, arrested cell cycle and decreased proliferation | r-μ | [ |
| MCF-7 | Cytoskeleton, Mitosis | Altered microtubule structure, prolonged cell cycle | r-μ | [ |
| MCF-7 | MCS Cytoskeleton | s-μ | [ | |
| CRL-2351 | Cell reparation and adhesion, MCS | s-μ | [ | |
| CRL-2351 | Morphology and gene expression, MCS | Upregulated | s-μ | [ |
| MCF- 7 | MCS formation and adhesion | Decreased E-cadherin in MCS, PP2 prevented MCS formation | s-μ | [ |
| MCF-7 | MCS formation, apoptosis | Upregulation o | s-μ | [ |
| MDA-MB231 | Phenotypic switch | G2/M inhibited and cyclin D1 decreased | s-μ | [ |
| MCF-7, MDA-MB231 | MCS formation | Vinculin and β-catenin are critical to form MCS | s-μ | [ |
| MCF-10A, MCF-7 | Apoptosis | increased AKT and ERK pathway activity, decreased apoptosis | s-μ | [ |
| MDA-MB231 | Cell cycle apoptosis | Increased lysosomal vesicles, cyclin D3, decreased Bcl-2 and MMP9 proteins. | s-μ | [ |
| MCF7 | Metastatis ability | Cell invasion and migration decreased | s-μ | [ |
| MDA-MB 231 | dysregulation extracellular vesicle | Proteomics show significant correlation with GTPases and proliferation | s-μ | [ |
Genes and proteins involved in prostate cancer cell spheroid formation under microgravity conditions.
| Cell Line | Biological Process | Genes/Proteins | Microgravity | Reference |
|---|---|---|---|---|
| DU145 | Cytoskeleton | Cytokeratins-8 and -18, actin, vimentin | s-µ | [ |
| DU145 | Regulatory and matrix proteins | EGF, EGF receptor, TGF-β1, TGF-β receptor, collagen IV and laminin | s-µ | [ |
| DU145 | Transduction-second messenger | DAG, ceramide, PA, PEt, choline, AA and cAMP | s-µ | [ |
| LNCaP | Prostate specific peptidase | PSA | s-µ | [ |
| PC-3 | Cell adhesion molecules | CD44 and E-cadherin | s-µ | [ |
| PC-3 | Epithelial marker | cytokeratin VIII | s-µ | [ |
| PC-3 | Collagen deposition | collagen IV | s-µ | [ |
| PC-3 | VEGF signaling | s-µ | [ | |
| PC-3 | Collagen deposition | s-µ | [ | |
| PC-3 | Focal adhesion |
| s-µ | [ |
| PC-3 | Cytokines | IL-1α, IL-1β, IL-6 and IL-8 | s-µ | [ |
Overview of results of studies with gastrointestinal cancers exposed to µg.
| Cell Line | Biological Process | Genes/Proteins/Pathways | Microgravity | Reference |
|---|---|---|---|---|
|
| ||||
| HT-29, HT-29KM, Co-culture with normal human colonic fibroblasts | Differentiation | proliferation at an accelerated rate, organizing themselves into 3D MCS (1.0–1.5 cm), signs of a well-differentiated colon tissue | RWV | [ |
| HT-29KM CCL 188 KM-12c and MIP-101 | Cell adhesion | µ | RWV | [ |
| MIP-101 | Proliferation, differentiation | The petri and RWV cultures continued to proliferate the full 14 d. | RWV with 5 mg/mL | [ |
| MIP-101 | Differentiation, Apoptosis, Proliferation | Rotation appears to increase apoptosis and decrease proliferation, whereas static 3D cultures in either unit or microgravity have less apoptosis, and reduced rotation in microgravity increases CEA expression | on Teflon-coated non-adherent surfaces (static 3D) or RWV either in r-µ | [ |
| HCT-116 | 3D liver metastasis model with CRC cells | In 2D they displayed an epithelial phenotype, and only after transition to the organoids did the cells present with a mesenchymal phenotype. | RWV | [ |
| HCT116 | 3D spheroids | Host-liver CRC- spheroids composed of primary human hepatocytes, MSC and HCT116 cells | RWV | [ |
| DLD1, HCT116 SW620 | Apoptosis | Apoptosis under s-µ | RCCS-HARV | [ |
| HCT 116 | Stemness regulators, differentiation | upregulation of markers like CD133/CD44, YAP nuclear localization and increase the number of polyploid giant cancer cells, Yamanaka factor upregulation | RCCS-HARV | [ |
| Caco-2 cells | Proteomics | 38 and 26 proteins differently regulated by simulated microgravity after 48 and 72 h lower NF-kB basal activation in s-µ | 2D clinostat | [ |
| LS180 | Tissue engineering, phytomedicine testing | 3D LS180 cell mini-tumors, suitable for drug testing | 2D Clinostat | [ |
|
| ||||
| HepG2 | 3D formation | Early stage of 3D assembly: changes in the expression of 95 genes (overexpression of 85 and downregulation in 10) | RCCS | [ |
| HepG2 | Gene expression | 139 genes significantly altered in s-µ | RCCS | [ |
| HepG2 | MCS formation, cytoskeleton, Gene expression | MCS up to 100 µm in diameter within 72 h and up to 1 mm with long-term culture. | RWV | [ |
| MHCC97H | MCS formation, Morphology | MCS: mirrored clinical pathological features of HCC in vivo: morphology, ultrastructure, protein production and secretion, glucose metabolism, tissue-specific gene expression, and apoptosis. | RWV | [ |
| MHCC97H | Co-culture of CRC cells and liver fragments | time-course analysis showed dynamic gene alterations: | RWV | [ |
| MHCC97H, Hep3B | Metastasis—low and high potential, gene expression | Differences between two HCC MCS types in gene expression patterns of adhesion molecules, matrix secretion, invasion etc. | RWV | [ |
| HepG2 | Apoptosis, cis-diamminedi-chloroplatinum (CDDP) | µ | Gravite (3D clinostat) | [ |
| HepG2/C3A | 3D model for genotoxicity testing of chemicals | 21-day old MCS: higher basal expression of genes encoding metabolic enzymes compared to monolayer culture. | dynamic clinostat bioreactor system (CelVivo BAM/bioreactor) | [ |
|
| ||||
| HGC-27 | Metabolomics | A total of 67 differentially regulated metabolites were identified, including upregulated and downregulated metabolites. | RCCS | [ |
| NOR-P1 | 3D tissues, apoptosis | s-µ | RCCS-4D | [ |
Figure 3F-actin cytoskeleton: (A) Lung cancer cells cultured under static 1g conditions stained with DAPI (blue nuclei) and labeling of F-actin with phalloidin (green colored cytoskeleton) and (B) MCS of LCC cultured in the iRPM.
Figure 4Phase contrast microscopy: (A) 5d, 1g FTC-133 TCC, (B) 5d RPM FTC-133 cells, MCS are visible (red arrows); (C) confluent and overgrown MCF-7 BC cells after 10 d at static 1g conditions, (D) 10-d RPM-exposure of MCF-7 revealed compact MCS (red arrows), but also glandular structures (blue arrows); (E) 7 d, 1g MDA-MB-231 BCC, (F) 7-d exposure of MDA-MB-231 triple negative BCC revealed 3D MCS; (G) 5 d, 1g PC-3 PCC and (H) compact 5 d MCS of PC-3 cells on the RPM (red arrows); magnification ×100.; scale bars: 50 µm.
Figure 5Schematic representation of the µg-induced in vitro metastasis model. When exposed to µg, adherent cancer cells downregulate focal adhesions. The cells detach and micro-metastasis-like tumor spheroids are formed. When gravity is restored, the spheroids reattach on their substrate.
Substances acting on the proteins detected in microgravity studies.
| Pharmacological Agent and Drugs | Target Protein | References |
|---|---|---|
| PP2 (4-amino-5-(4-chlorophenyl)-7-(dimethylethyl) pyrazolo [3,4-d] pyrimidine) | Proto-oncogene tyrosine-protein kinase Src | [ |
| Daidzein | Caveolin-1 | [ |
| Camptothecin | Ubiquitin-like protein ISG15 | [ |
| SP600125 | Mitogen-activated protein kinase 8/JNK1 | [ |
| Dexamethasone, BAY 11-7082 | NFκB p65 | [ |
| GSK2256098, MPAP | Focal adhesion kinase 1 | [ |
| MT189 | Paxillin | [ |
| Cetuximab, Panitumumab, Sym004 | EGF receptor | [ |
| Interleukin-6 Inhibitor (Siltuximab), Tocilizumab | Interleukin 6, IL-6 receptor | [ |
| HuMax-IL8 (BMS-986253) antibody, CXCL8-IP10 (Analogue), Reparixin | CXCL8, CXCL8 receptor | [ |
| AKT Inhibitor, Ipatasertib | AKT | [ |
| mTOR inhibitors | mTOR | [ |
| Curcumin | HMOX-1 | [ |
| TM5441 | Plasminogen activator inhibitor 1 | [ |
| UK370106 | Stromelysin, (MMP3) | [ |
| Monoclonal antibody | Integrin-ß1, Fibronektin, CD44, E-cadherin, ICAM-1, VEGF | [ |
Figure 6Illustration of a Multi-Omics workflow in cancer research. Starting with the MCS development enabled by µg, the subsequent omics analyses using NGS technology and mass spectrometry generate multi-omics data sets that are finally processed integratively in AI-based analyses. The graphic under the term AI is a simplified representation of an artificial neural network.
Figure 7PRISMA 2020 flow diagram: results of the literature search (different types of cancer cells exposed to microgravity/space) for this comprehensive review.